Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3657367 | 0.87 | MEN1 (0.55) | MEN1KMT2ALMNAPOLB | |
| SCHEMBL3660786 | 0.85 | KMT2A (0.57) | MEN1KMT2ALMNAGAA | |
| SCHEMBL3658793 | 0.85 | KMT2A (0.64) | MEN1KMT2APOLB | |
| SCHEMBL3658552 | 0.84 | FPR2 (0.56) | MEN1KMT2APOLBTDP1 | |
| SCHEMBL3655610 | 0.83 | MEN1 (0.65) | MEN1KMT2ALMNAPOLBTDP1 | |
| SCHEMBL3663379 | 0.83 | KMT2A (0.70) | MEN1KMT2APOLB | |
| SCHEMBL3656416 | 0.82 | KMT2A (0.63) | MEN1KMT2ALMNAPOLB | |
| SCHEMBL3663111 | 0.82 | MEN1 (0.62) | MEN1KMT2ALMNAPOLBTDP1 | |
| SCHEMBL3659564 | 0.81 | POLB (0.63) | MEN1KMT2ALMNAPOLBTDP1 | |
| SCHEMBL3657751 | 0.81 | MEN1 (0.58) | MEN1KMT2ALMNAPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212314-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050200-A1 | IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099243-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099243-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLCO1B1, SLCO1B3 | MEN1 155/4885KMT2A 2020/4885LMNA 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.